<DOC>
	<DOCNO>NCT00744627</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety vortioxetine , daily ( QD ) , adult Generalized Anxiety Disorders .</brief_summary>
	<brief_title>Efficacy Safety Vortioxetine ( Lu AA21004 ) Treatment Generalized Anxiety Disorder Adults .</brief_title>
	<detailed_description>The drug test study call Vortioxetine . Vortioxetine test treat anxiety adult general anxiety disorder ( GAD ) . This study look GAD relief people take vortioxetine . The study enrol 301 patient . Participants randomly assign ( chance , like flip coin ) one two treatment groups—which remain undisclosed patient study doctor study ( unless urgent medical need ) : - Vortioxetine 5 mg - Placebo ( dummy inactive pill ) - capsule look like study drug active ingredient . All participant ask take one capsule time day throughout study . This multi-center trial conduct Europe . The overall time participate study 13 week . Participants make 7 visit clinic , contact telephone 4 week last dose study drug follow-up assessment .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Vortioxetine</mesh_term>
	<criteria>Suffers primary diagnosis Generalized Anxiety Disorder accord Diagnostic Statistical Manual Mental Disorders , Fourth Edition , Text Revision ( DSMIVTR ) criterion . Has Hamilton Anxiety Scale total score ≥20 Screening Baseline . Has Hamilton Anxiety Scale score ≥2 Item 1 ( anxious mood ) Item 2 ( tension ) Screening Baseline . Has MontgomeryÅsberg Depression Rating Scale total score ≤16 Screening Baseline . Male females childbearing potential sexually active agree use adequate contraception Screening throughout duration study 1 month last dose study medication . Has receive investigational compound &lt; 30 day Screening 5 halflives prior Screening . Has receive Lu AA21004 previous clinical study therapeutic agent . Has 1 follow : Any current psychiatric disorder Generalized Anxiety Disorder define DSMIVTR . Current past history : manic hypomanic episode , schizophrenia psychotic disorder , include major depression psychotic feature , mental retardation , organic mental disorder , mental disorder due general medical condition define DSMIVTR . Any substance disorder ( except nicotine caffeine ) within previous 6 month define DSMIVTR . Presence history clinically significant neurological disorder ( include epilepsy ) . Neurodegenerative disorder ( Alzheimer 's disease , Parkinson 's disease , multiple sclerosis , Huntington disease , etc ) . Any Axis II disorder might compromise study . Is required take exclude medication anticipate participant require treatment least 1 disallow concomitant medication study include : Nonsteroidal antiinflammatory drug Rifampin Macrolide antibiotic Hormones Hypoglycemic agent Insulin Systemic steroid Antineoplastics Antiobesity agent Antidiarrheal agent ( episodic use allow ) Antifungal agent ( episodic topical use allow ) Antihistamines ( episodic use loratadine , desloratadine , cetirizine allow ) Cough/cold agent ( episodic use allow preparation contain pseudoephedrine narcotic NOT allow ) Diuretics ( episodic use allow ) Has significant risk suicide accord investigator 's opinion score ≥5 item 10 ( suicidal thought ) MontgomeryÅsberg Depression Rating Scale make suicide attempt previous 6 month . Has previously fail respond adequate treatment selective serotonin reuptake inhibitor and/or serotoninnorepinephrine reuptake inhibitor . Has receive electroconvulsive therapy within 6 month prior Screening . Is currently receive formal cognitive behavioral therapy , systematic psychotherapy , plan initiate therapy study . Has clinically significant unstable illness , example , hepatic impairment renal insufficiency , cardiovascular , pulmonary , gastrointestinal , endocrine , neurological , rheumatologic , immunologic , infectious , skin subcutaneous tissue disorder , metabolic disturbance . Has alanine aminotransferase , aspartate aminotransferase bilirubin level &gt; 1.5 time upper limit normal . Has serum creatinine &gt; 1.5 time upper limit normal . Has previous history cancer remission le 5 year prior first dose study medication . This criterion include participant basal cell stage I squamous cell carcinoma skin . Has clinically significant abnormal vital sign determine investigator . Has 1 laboratory value outside normal range , base blood urine sample take Screening , consider investigator clinically significant . Has thyroid stimulate hormone value outside normal range Screening deem clinically significant investigator . Has abnormal electrocardiogram determine central reader confirm clinically significant investigator . Has disease take medication , opinion investigator , could interfere assessment safety , tolerability , efficacy . Has previously participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Generalized Anxiety Disorder</keyword>
	<keyword>Anxiety Disorders</keyword>
	<keyword>Drug Therapy</keyword>
</DOC>